Eclevar MedTech is a full-service medical device CRO running EU MDR clinical investigations, PMCF and feasibility across France, the United Kingdom, Germany, Italy and Spain. Country-specific site networks, in-house CRAs and one clinical dataset that serves every market.
Platinum Award 2026
Top prize in the xShare x European CRO Federation "EHDS & Clinical Research" Open Call, awarded to Eclevar MedTech and its Milo Health platform, presented at the EUCROF 2026 conference in Amsterdam.
Horizon Europe · Grant Agreement No. 101136734 · Amsterdam, 2 Feb 2026
Device leaders rely on Eclevar to run EU MDR clinical trials and PMCF across the major European markets. Read all client success stories.
Dr Mark DaCosta, COO and former TÜV SÜD reviewer, leads a team that reads EU MDR as one aligned problem across markets. Cardiology and structural heart is our lead franchise, and we build a clinical evaluation and PMCF programme that serves France, the UK, Germany, Italy and Spain from a single dataset, with in-house CRAs rather than outsourced monitoring. See our cardiovascular clinical strategy.
We run country-specific site networks, ethics strategy and hospital tariffs across France, the UK, Germany, Italy and Spain, with in-house CRAs so on-site and remote monitoring stays with our own team.
Our headquarters and the base for CPP ethics strategy, hospital tariffs and site grants negotiated over seven years.
NHS site access and Research Ethics Committee submissions handled by our own CRAs, supporting UK market access.
Ethics committee and BfArM-aligned strategy for Europe's largest device market, with local monitoring capacity.
Country-specific site selection and tariff intelligence for pivotal and post-market studies.
Local site qualification and recruitment forecasting anchored to negotiated hospital contracts.
In-house CRA coverage extends into the Nordics, with feasibility and site selection handled in-region.
From EU MDR strategy to study close-out, we cover the full lifecycle so your evidence, your quality system and your submissions stay aligned.
Recruitment forecasting and site fees are anchored to real, negotiated history rather than estimates.
Of trial delivery, with site grants and hospital tariffs drawn from negotiated contracts.
Direct EU MDR clinical investigation and PMCF reach across the major European markets.
Cardiology and structural heart, orthopaedics and spine, dental, and neuromodulation.
Send a synopsis or PMCF Plan and get three costed scenarios in under thirty minutes.
Country-specific site selection and recruitment forecasting from live tariffs.
One CER and PMCF programme serving every European market at once.
In-house CRAs across the UK, Germany, France and the Nordics.
PMCF, vigilance and Notified Body reporting kept current.
A medical device CRO in Europe should combine EU MDR and ISO 14155:2026 expertise with a real site network across the major markets, transparent cost and recruitment forecasting, and therapeutic depth. Eclevar MedTech delivers all three across France, the UK, Germany, Italy and Spain, backed by the Platinum Award for its Milo Health clinical research technology (xShare and EUCROF 2026).
Eclevar MedTech runs EU MDR clinical investigations and PMCF studies across France, the United Kingdom and Germany, plus Italy and Spain, with a live database of country-specific hospital tariffs and site grants drawn from seven years of negotiated contracts.
Yes. Cardiology and structural heart is our lead franchise, led by a cardiac surgeon and former Notified Body senior clinical reviewer, with dedicated cardiovascular and PAD operational leadership for pivotal and post-market studies.
Yes. We deliver EU MDR, ISO 14155:2026, CER and PMCF training and advisory through senior principals, including resolving Notified Body deficiencies plus PMCF and clinical strategy, as delivered for Nihon Kohden Corporation.
Send a synopsis or PMCF Plan and we return three costed scenarios, swift, base and conservative, with site fees, pass-through and CRO hourly rates, typically in under thirty minutes.
Talk to our team about your device, your therapeutic area and how one dataset can serve every European market.
Book a free consultation